LLY · News · 20261113N
Product Launch - Oral GLP-1
ELI LILLY & Co · 2026-11-13 · Importance 53 · Surprise 60
China's National Medical Products Administration approved Lilly's orforglipron, marketed as Foundayo, making it the first oral GLP-1 obesity treatment available in China. The once-daily pill offers adults with obesity or overweight an alternative to injections for chronic weight management. A report cited China's National Health Commission estimate that more than 65% of the population could be overweight or obese by 2030, and identified Novo Nordisk, Pfizer and Innovent Biologics as competitors. Lilly had committed $3 billion to expand manufacturing in China to support oral GLP-1 supply.
Key facts
- Marketed as Foundayo, Eli Lilly’s orforglipron is a once-daily pill and the first oral GLP-1 treatment for obesity available in China. source